Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
15 sept. 2024 08h45 HE
|
Lantheus Holdings, Inc.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3%...
Lantheus Appoints Julie Eastland as New Board Member
05 sept. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find,...
Lantheus Appoints Jamie Spaeth as Chief People Officer
08 juil. 2024 08h30 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus Announces Executive Appointments to Accelerate Innovation
15 mai 2024 16h30 HE
|
Lantheus Holdings, Inc.
Jeffrey S. Humphrey, MD appointed Chief Medical Officer;Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”)...
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
11 janv. 2024 08h00 HE
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling...
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
09 janv. 2024 08h00 HE
|
Lantheus Holdings, Inc.
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective...
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
09 janv. 2024 07h55 HE
|
Lantheus Holdings, Inc.
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023...
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
25 juil. 2023 06h06 HE
|
Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
13 sept. 2022 08h06 HE
|
Lantheus Holdings, Inc.; GE Healthcare
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)Trial also met its first key secondary endpoint,...
Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer
15 juin 2022 09h00 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanchfield has been promoted to...